AstraZeneca Pharma India Limited submitted a press release to BSE Limited and National Stock Exchange of India Ltd. in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, announcing its financial results for the quarter and half year ended September 30, 2026.

Financial Performance

The company reported strong financial performance with 30% year-over-year growth:

Q2 FY26-27 (Jul'26-Sep'26) Results:

  • Total revenue from operations: ₹7,291 Mn
  • Oncology segment: ₹5,085 Mn
  • Biopharmaceuticals segment (CVRM, R&I and V&I): ₹1,610 Mn
  • Rare Diseases segment: ₹204 Mn

H1 FY26-27 (Apr'26-Sep'26) Results:

  • Total revenue from operations: ₹14,119 Mn (30% growth from previous financial year)
  • Oncology segment: ₹9,733 Mn
  • Biopharmaceuticals segment: ₹3,229 Mn
  • Rare Diseases segment: ₹347 Mn

Comparative Performance (Previous Year):

  • Q2 FY25-26 (Jul'25-Sep'25): ₹5,591 Mn total revenue
  • H1 FY25-26 (Apr'25-Sep'25): ₹10,854 Mn total revenue

Management Commentary

Mr. Praveen Rao Akkinepally, Country President & Managing Director, stated that the growth demonstrates the strength of AstraZeneca's science-led portfolio and the company's ability to translate innovation into meaningful impact for patients in India. He emphasized the company's focus on building strong partnerships across the healthcare ecosystem to bring innovative medicines to more patients faster.

Regulatory Approvals

The company received six new regulatory approvals in Q2 FY26-27:

Trastuzumab deruxtecan approvals:

1. For adults with HER2-positive Stage II or III early breast cancer (following taxane, trastuzumab, and pertuzumab)

2. For adults with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment

3. In combination with pertuzumab for first-line treatment of adult patients with unresectable or metastatic HER2 positive (IHC3+ or ISH+) breast cancer

Benralizumab approval:

  • For treatment of patients aged 12 years and older with hypereosinophilic syndrome without an identifiable nonhaematologic secondary cause

Acalabrutinib approvals:

1. In combination with venetoclax with or without obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL)/small lymphocytic lymphoma (SLL)

2. In combination with bendamustine and rituximab for previously untreated mantle cell lymphoma (MCL) in adults not eligible for autologous stem cell transplant (ASCT)

Strategic Initiatives

Andhra Pradesh MoU:

  • Signed Memorandum of Understanding with Government of Andhra Pradesh to build a 360-degree oncology care model
  • Focus on early detection and personalized treatment
  • Establishment of 'Integrated Genomic Solutions Centre (IGSC)' for NGS-based biomarker testing in lung and breast cancers
  • Integration of AI-powered chest X-ray solution into routine public health workflows

Telangana MoU:

  • Signed Memorandum of Understanding with Government of Telangana for AI-enabled lung cancer screening
  • Deployment of Qure.ai's AI-powered chest X-ray solution across public healthcare facilities
  • Initiative to roll out across 20 public health facilities in urban and rural settings
  • Includes training and upskilling of healthcare professionals

K+ Connect Initiative:

  • Launched pan-India multidisciplinary initiative for hyperkalaemia management in Heart Failure and Chronic Kidney Disease
  • Brings together clinicians across specialties for coordinated approach to risk identification, monitoring and management

India Coronary Conquest (ICC) 2026:

  • Launched in collaboration with STEMI India
  • National complex PCI challenge to strengthen evidence-based learning and peer exchange among interventional cardiologists
  • Aims to support capability building in advanced cardiovascular care through case-based learning

Recognitions

OPPI India Awards 2026:

  • Received Medical Excellence Award for contributions to Rare Disease
  • Runner-up in Marketing Excellence category for Hyperkalaemia & Kidney Care initiative in Biopharmaceuticals

ETHRWorld Employee Experience Awards 2026:

  • Gold Award in Exceptional Employee Experience in Driving Business Impact category

Compliance Details

The disclosure was made under Regulation 30 of SEBI (LODR) Regulations, 2015. The document was digitally signed by Tanya Sanish, Company Secretary & Compliance Officer (ACS No.: A25784) on November 5, 2026.

Media Contacts

  • Pooja Behuria: pooja.behuria@astrazeneca.com
  • Gunjan Gupta: gunjan.gupta@astrazeneca.com